藏药二十味沉香丸的质量标准研究

目的 建立常用藏药二十昧沉香丸的鉴别和含量测定方法。方法 采用薄层色谱法和高效液相色谱法。结果 建立了二十味沉香丸中沉香、马钱子、诃子、红花、降香等药材的薄层色谱鉴别方法，并采用HPLC测定了该藏药制剂中诃子等药材中的有效成分没食子酸的含量，其回归方程为：A=50205C-104．18(r=0．9995)，没食子酸的平均回收率为100．64％，RSD=1．13％(n=5)。结论 鉴别与含量测定方法简便、准确，可用于二十味沉香丸的质量控制。     

益气聪明丸质量标准研究

目的 为控制益气聪明丸的质量,建立黄芪、黄柏和升麻的薄层色谱鉴别和葛根的高效液相含量测定方法.方法 采用薄层色谱法,鉴别黄芪药材中的黄芪甲苷、黄柏药材中的盐酸小檗碱、升麻药材中的异阿魏酸;用高效液相法测定葛根药材中的葛根素含量.结果 鉴别方法操作简单,专属性强,重复性好,阴性对照无干扰;含量测定方法操作简单,准确,葛根素在0.114～4.560 μg之间呈良好的线性关系,葛根素的回收率为99.03%.结论 本质量标准能有效地控制益气聪明丸的质量.     

藏药十一味金色丸的鉴别和没食子酸的含量测定

目的　建立藏药十一味金色丸的鉴别和没食子酸的测定方法。方法　采用薄层色谱法和高效液相色谱法。结果　鉴别了十一味金色丸中诃子、角茴香、铁棒锤、波棱瓜子和榜嘎等药材 ,并采用HPLC法测定了诃子的有效成分没食子酸的含量 ,其回归方程为 :A =5× 10 6C - 7 6× 10 3 (r=0 .9998) ,没食子酸的平均回收率为 10 1.4 8% ,RSD =1.16 % (n =5 )。结论　所用方法简便、准确 ,可用于十一味金色丸的质量控制。     

解郁安神丸的质量标准研究

目的 建立解郁安神丸质量控制方法用于产品质量控制.方法 采用薄层色谱法定性鉴别解郁安神丸中的夏枯草、延胡索、泽泻,采用高效液相色谱法测定解郁安神丸王不留行黄酮苷含量.结果 采用薄层色谱法建立了产品的定性鉴别方法,采用该方法进行定性鉴别特征斑点清楚,具有较好的重现性和专属性;采用高效液相色谱法建立了产品含量测定方法,王不...     

桃红通瘀丸的质量控制标准研究

目的 采用薄层鉴别法和高效液相色谱法建立桃红通瘀丸质控方法用于产品质量控制.方法 采用薄层色谱法定性鉴别桃红通瘀丸中的川芎、北柴胡、醋延胡索,采用高效液相色谱法测定桃红通瘀丸桃仁中苦杏仁苷的含量.结果 采用薄层色谱法确定了川芎、北柴胡、醋延胡索定性鉴别方法;采用高效液相色谱法建立了产品含量测定方法,苦杏仁苷在15.83...     

气管炎丸的质量标准研究

目的完善气管炎丸的质量标准,提高气管炎丸的可控性。方法采用薄层色谱法对气管炎丸中五味子、青黛进行了定性鉴别;采用高效液相色谱法测定气管炎丸中黄芩药材中黄芩苷的含量,色谱柱采用zorbax SB-C18(4.6mm×150mm,5μm),流动相为甲醇-0.0 4%磷酸(40∶60),流量0.8 m L·min-1,检测波长280 nm。结果薄层鉴别供试品图谱中的色谱斑点清晰,且阴性样品无干扰。黄芩苷在0.026272μg~0.6568μg范围内有良好的线性关系(r=0.9999),平均加样回收率为97.90%(n=6)。结论所建立薄层鉴别及含量检测指标合理科学,所建立的方法操作简便,具有实用性,完善了气管炎丸的质量标准,提高了产品的可控性。     

复方玉驹胶囊的质量标准研究

目的 :建立复方玉驹胶囊的鉴别与含量测定方法。方法 :分别以白蚁巢标准药材和乌药内酯为对照 ,采用薄层色谱法进行鉴别 ;反相高效液相色谱法测定含量 ,色谱柱为Shim packCLC ODS柱 ,检测波长 2 0 8nm ,流动相为乙腈 含0 1%磷酸的水 (5 0∶5 0 ) ,柱温为室温 ,流速 0 5ml·min 1。结果 :薄层色谱鉴别法专属性强 ,HPLC法测定含量精密度高 ,重复性好 (RSD <1 5 % ) ,平均回收率为 10 0 8% ,标准曲线回归方程为Y =- 40 19 3 +5 978C ,r =0 9999。结论 :鉴别与含量测定方法简便、准确 ,可用于复方玉驹胶囊的质量控制     

高效液相色谱法测定珍宝丸中栀子苷含量

目的 建立珍宝丸中栀子苷含量的测定方法。方法采用高效液相色谱法,色谱柱为ZorbaxSB-C18柱（250mm×4．6mm,5μm）,流动相为乙腈-0．1％磷酸（10：90）,流速为1．0mL／min,检测波长为238nm。结果栀子苷进样量在0．0447～5．8240μg范围内与峰面积线性关系良好,r=1．0000,平均回收率为99．61％,RSD为1．78％（n=6）。结论方法简便、准确、重现性好,适用于珍宝丸的质量控制。     

苏木药材质量标准研究

目的进行苏木药材的质量标准研究，建立苏木药材的TLC鉴别和巴西苏木红素的含量测定方法。方法采用TLC法定性鉴别苏木药材；采用HPLC法建立苏木药材中巴西苏木红素的含量测定方法。结果法巴西苏木红素在0．2～1．5μg线性关系良好，回归方程为Y=2．534×10^4X＋6．647×10^4（r=0．9992）；平均加样回收率为101．72％，RSD=1．12％（n=6），6批苏木药材中巴西苏木红素的含量在0．205％～0．328％，TLC鉴别结果满意。结论该方法操作简便、准确快速、重现性好，有助于苏木药材的质量控制。     

藏药二十八味槟榔丸的鉴别及没食子酸的含量测定

目的　建立更为规范的藏药二十八味槟榔丸的质量标准。方法　采用TLC和HPLC。结果　TLC鉴别了二十八味槟榔丸中的槟榔、荜茇、诃子、姜黄、圆柏、小檗皮等 6味药材 ,并通过HPLC测定了 3批制剂中诃子的有效成份没食子酸的含量 ,分别为 0 .2 1 1 %、0 .2 0 9%、0 .2 1 6 % ,在 9.3～ 32 .5μg·ml- 1 的浓度范围内 ,线性关系良好 (r=0 9997)。平均回收率为 98.4% ,RSD =1 .2 7%。结论　鉴别的专属性明显提高 ,含量测定方法简便、准确。     

Nachweis einiger Heilmittel in der Kniegelenksynovialflüssigkeit

Zusammenfassung Mittels Gaschromatographie und Dünschichtchromatographie wiesen die Autoren 11 Substanzen nach, welche durch Injektion oder nach Verabreichung per os in die Kniegelenksynovialflüssigkeit eindrangen. In ihrer Aufstellung konnten sie eine direkte Beziehung zwischen Struktur sowie chemischphysikalischen Eigenschaften der Substanz und ihrer Fähigkeit, aus dem Blut in die Kniegelenksynovialflüssigkeit einzudringen, nicht nachweisen, außer der Tatsache, daß Substanzen mit starker Affinität zu Eiweißstoffen erst in höheren Dosen nachweisbar waren.     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Emerging drugs for epilepsy

Epilepsy affects ≤ 1% of the world's population. Antiepileptic drugs (AEDs) are the mainstay of treatment, although more than a third of patients are not rendered seizure free with existing medications. Uncontrolled epilepsy is associated with increased mortality and physical injuries, and a range of psychosocial morbidities, posing a substantial economic burden on individuals and society. Limitations of the present AEDs include suboptimal efficacy and their association with a host of adverse reactions. Continued efforts are being made in drug development to overcome these shortcomings employing a range of strategies, including modification of the structure of existing drugs, targeting novel molecular substrates and non-mechanism-based drug screening of compounds in traditional and newer animal models. This article reviews the need for new treatments and discusses some of the emerging compounds that have entered clinical development. The ultimate goal is to develop novel agents that can prevent the occurrence of seizures and the progression of epilepsy in at risk individuals.     

盐酸达泊西汀中甲磺酸甲酯、甲磺酸乙酯及甲磺酸异丙酯的顶空毛细管GC-ECD法测定

建立了衍生化顶空毛细管气相色谱-电子捕获检测器(ECD)法测定盐酸达泊西汀中的甲磺酸甲酯(MMS)、甲磺酸乙酯(EMS)和甲磺酸异丙酯(IMS).应用碘化钠衍生技术,使用PW-5毛细管柱,载气为氮气,ECD检测,程序升温.MMS、EMS和IMS分别在0.03～0.30、0.05～0.50和0.05～0.50 μg/ml浓度范围内线性关系良好,平均回收率分别为63.5％、100.3％和96.2％,最低检测限分别为0.30、0.50和0.50 ng/ml.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.